A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
University of Thi-Qar Journal of Medicine
: Cardiotoxicity is a well recognized adverse event of trastuzumab. This study was designed to evaluate the frequency of decline in left ventricular ejection fraction (LVEF) to less than 50% in patients with breast cancer who have received trastuzumab in a daily practice setting. Methods : Retrospective observational study of 116 patients with HER2 positive breast cancer treated with trastuzumab in one center Results : Left ventricular ejection fraction decline to less than 50% was observed indoi:10.32792/utq/utjmed/15/1/9 fatcat:r7uq43fr7nemda6bdldem5cs5i